Bioverativ Inc (NASDAQ:BIVV) was the target of some unusual options trading on Tuesday. Traders bought 2,030 put options on the company. This is an increase of approximately 2,376% compared to the typical volume of 82 put options.

A number of hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. bought a new stake in Bioverativ in the third quarter valued at approximately $137,000. TCI Wealth Advisors Inc. bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $186,000. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $190,000. Canada Pension Plan Investment Board bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $194,000. Finally, ACG Wealth bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $205,000. Institutional investors and hedge funds own 96.95% of the company’s stock.

A number of research firms recently commented on BIVV. Zacks Investment Research raised Bioverativ from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Morgan Stanley reissued an “underweight” rating and set a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Royal Bank Of Canada assumed coverage on Bioverativ in a research note on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price for the company. Finally, Evercore ISI assumed coverage on Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Bioverativ has an average rating of “Hold” and a consensus target price of $60.93.

Shares of Bioverativ (BIVV) opened at $50.57 on Friday. Bioverativ has a twelve month low of $40.00 and a twelve month high of $64.41.

Bioverativ (NASDAQ:BIVV) last announced its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. The firm’s revenue was up 27.2% compared to the same quarter last year. research analysts anticipate that Bioverativ will post 2.45 EPS for the current year.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/bioverativ-sees-unusually-high-options-volume-bivv/1726610.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.